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Abstract (n= 250) 
 
Omentin is a novel biomarker shown to exert metabolic, inflammatory and immune-related 
properties, and thereby could be implicated in the risk of colorectal cancer (CRC). So far, the 
association between omentin and CRC risk has not been evaluated in prospective cohort 
studies. We investigated the association between pre-diagnostic plasma omentin 
concentrations and risk of CRC in a case-cohort comprising 251 incident CRC cases 
diagnosed over a mean follow-up time of 10.4 years and 2,295 persons who remained free of 
cancer in the European Prospective Investigation into Cancer and Nutrition-Potsdam study. 
Hazard ratios as a measure of relative risk (RR) and 95% confidence intervals (CI-s) were 
computed using a Prentice modified Cox regression. In a multivariable model adjusted for 
age, sex, education, dietary and lifestyle factors, body mass index (BMI) and waist 
circumference, higher omentin concentrations were associated with a higher CRC risk 
(RRcontinuously per doubling of omentin concentrations=1.98, 95%CI: 1.45-2.73). Additional adjustment for 
metabolic biomarkers, including glycated hemoglobin, high-density lipoprotein cholesterol 
and C-reactive protein, did not alter the results. In stratified analyses, the positive association 
between omentin and CRC risk was retained in participants with BMI < 30 (RRcontinuously per 
doubling of omentin concentrations=2.26; 95%CI: 1.57-3.27), whereas among participants with BMI ≥ 
30 no association was revealed (RRcontinuously per doubling of omentin concentrations =1.07; 95%CI: 0.63-
1.83; Pinteraction= 0.005). These novel findings provide the first lines of evidence for an 
independent association between pre-diagnostic omentin concentrations and CRC risk and 
suggest a potential interaction with the adiposity state of the individual.  
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Introduction  
Omentin - also known as intelectin-1 or intestinal lactoferrin receptor ITLN1 - is a novel 34 
kDa protein described to exert metabolic, inflammatory and immune-related properties, which 
thereby could be implicated in the development of colorectal cancer [CRC] (1-4). There are 
two genes, omentin-1 and omentin-2, that are adjacent to each other on chromosome 1q band 
23 and that share 83% of amino acid sequences, (5); however, omentin-1 is the major 
circulating isoform in human plasma. Therefore, we refer to omentin-1 as omentin. Omentin 
is mainly produced in the goblet cells among the epithelial lining of organs, such as the 
intestines, colon, lung and heart, and is highly abundant in human plasma circulation (6-8). 
Omentin expression is also observed in the mesothelial cells on adipose tissue (8). 
Paradoxically, while omentin is highly expressed in visceral fat tissue, circulating plasma 
omentin concentrations were shown to be down-regulated in obesity-linked metabolic 
disorders including insulin resistance, glucose intolerance and type 2 diabetes (1,9). In obese 
and metabolically afflicted people, omentin was positively correlated with adiponectin and 
high-density lipoprotein cholesterol and inversely correlated with triglyceride and leptin 
levels (10-14). The underlying regulatory mechanisms mediating omentin dysregulation in 
obesity are unknown, but could potentially include adipocyte hypertrophy, inflammation and 
oxidative stress, as well as a failure of transcriptional regulation. Conversely, in cancer 
models omentin was suggested to promote cancer cell growth via triggering genomic 
instability (15) and PI3K/Akt (phosphatidylinositol-3 kinase downstream effector) signaling 
pathways (16,17). These cancer-promoting effects of omentin have been described 
independent of its abilities to regulate obesity-induced metabolic risk (18). Furthermore, 
higher omentin levels have been associated to inflammatory bowel disease, immune 
responses, and infection as potentially predisposing factors to CRC development (19). These 
controversial findings could reflect dual roles of omentin depending on the adiposity state of 
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the individual. However, prospective epidemiological studies to evaluate these associations in 
humans are currently lacking.   
Within this context, we aimed to explore the association of circulating omentin concentrations 
with risk of CRC, and to test whether such an association may be independent of adiposity 
parameters [body mass index (BMI) and waist circumference] and metabolic biomarkers of 
relevance for CRC risk [i.e. glycated hemoglobin (HbA1c), high-density lipoprotein 
cholesterol (HDL-C) and high sensitivity C-reactive protein (hsCRP)] (20-22). In addition, we 
were interested to explore whether potential associations may differ according to levels of 
adiposity and associated metabolic risk factors.  
Materials and Methods 
Study population  
The European Prospective Investigation into Cancer and Nutrition (EPIC) -Potsdam study is 
part of the multicenter prospective cohort study EPIC. In Potsdam, Germany, 27,548 
individuals (16,644 women and 10,904 men) were recruited from the general population 
between 1994 and 1998. The age range was 35–64 years in women and 40–64 years in men 
(23). The baseline examination included anthropometric measurements and by qualified 
medical personnel, blood sampling, a self-administered validated food-frequency 
questionnaire, and a personal interview, including questions about prevalent diseases and 
sociodemographic and lifestyle characteristics (24). Written informed consent was obtained 
from all study participants a priori, and the study was approved by the ethics committee of the 
Medical Society of the State of Brandenburg, Germany (25).  
Case ascertainment 
In the course of the active follow–up, participants were contacted every two years, with 
response rates ranging between 90% and 96% per follow-up round (26). Follow-up 
questionnaires were sent out every 2–3 years to identify incident cases of CRC. Cancer cases 
during follow-up were identified by a combination of methods including: health insurance 
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records, cancer and pathology registries, and by active follow-up directly through study 
participants or through next-of-kin. All incident cases of CRC identified during follow-up 
were verified by questionnaires that were mailed to the physicians. Thereby, information 
about the date and the type of diagnosis, about the diagnostic tests, and about the treatment 
was obtained. Cancer incidence data were coded according to the 10th revision of the 
International Statistical Classification of Diseases, Injuries and Causes of Death (27) and the 
second revision of the International Classification of Diseases for Oncology (28). According 
to the International Classification of Diseases, Tenth Revision (ICD-10), proximal colon 
tumors include those in the cecum, appendix, ascending colon, hepatic flexure, transverse 
colon, and splenic flexure (ICD-10 codes C18.0–18.5); distal colon tumors include those in 
the descending colon (ICD-10 code C18.6) and sigmoid colon (ICD-10 code C18.7); and 
rectal tumors are those occurring at the rectosigmoid junction (ICD-10 code C19) or in the 
rectum (ICD-10 code C20). Only participants having had a diagnosis of CRC that was 
confirmed by a physician and a diagnosis date after the baseline examination were considered 
as incident CRC cases. Non-melanoma skin cancers were excluded from the analysis. For the 
current analysis, we considered follow-up as the time between date of enrollment and date of 
diagnosis of colorectal cancer, death, or last complete follow-up. Within a mean follow-up 
time of 10.4 (±2.1) years, 279 participants developed incident CRC.   
Case-cohort study 
The current prospective case-cohort study is based on a subcohort of 2,500 individuals 
randomly sampled from the original cohort of the EPIC-Potsdam study population and 279 
CRC cases (including 40 ‘internal’ subcohort cases) (29). Out of the subcohort and the cases, 
for the current analysis, participants with prevalent cancer at baseline (n=138), incomplete 
follow–up information (n = 69), and missing measurements for omentin concentrations at 
study baseline (n = 26) were excluded. Thus, the current analysis is based on 251 incident 
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CRC cases and 2295 non-case participants (Supplementary Figure 1). We considered recent 
recommendations for case-cohort study reporting in data analysis and reporting (30). 
Baseline anthropometrics and lifestyle characteristics 
Weight, height, and waist-circumference were measured by trained interviewers with 
standardized methods described elsewhere (26). Waist circumference was assessed by 
midway measurements between the lower rib margin and the superior anterior iliac spine to 
the nearest 0.5 cm. Body mass index was calculated by weight (kg) divided by squared height 
(m). Information on educational attainment, smoking, occupational activity level, and leisure 
time physical activity were assessed with a self-administered questionnaire and a personal 
interview by trained interviewers using a computer-assisted interview (31). We considered 
sport activities and cycling as leisure time activities, both calculated as the average time spent 
per week during the 12 months before the baseline recruitment. Dietary habits including 
alcohol consumption were assessed by a validated food frequency questionnaires (31). 
Measurement of biochemical parameters 
At baseline, 30 mL of venous blood was taken from each participant and, after fractionation 
into serum, plasma (collected on citrate, 10% of total volume), leukocytes, and erythrocytes 
immediately stored in tanks of liquid nitrogen (approximately -196°C) or deep freezers (-
80°C) (23). Plasma omentin concentrations were measured in citrate plasma sample by a 
sandwich enzyme linked immunosorbent assay (Human Omentin-1 ELISA, BioVendor, Brno, 
Czech Republic) at the Institute of Clinical Chemistry and Pathobiochemistry, Otto von 
Guericke University, Magdeburg, Germany. The linear range of the assay was reported to be 
50-644 ng/mL. The inter- and intra-assay coefficients of variation varied within 3.2% - 4.1% 
and 4.4% -4.8%, respectively, with a limit of detection of 0.5 ng/mL according to the 
manufacturer. Preliminary analyses suggested an excellent reliability of omentin over 4 
months period indicated by an intraclass correlation coefficient (ICC) of 0.83 [95% CI 0.78 - 
0.87] (32). Plasma levels of glucose, HDL-C, triglycerides, γ-glutamyltransferase, and fetuin-
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A and erythrocyte levels of HbA1c were measured with the automatic ADVIA 1650 analyzer 
(Siemens Medical Solutions, Erlangen, Germany). For determination of fetuin-A, an 
immunoturbidimetric method was used with specific polyclonal goat anti-human fetuin-A 
antibodies to human fetuin-A (BioVendor Laboratory Medicine, Modreci, Czech Republic). 
Adiponectin was determined with an enzyme-linked immunosorbent assay from Linco 
Research, St Charles, Missouri in 2008. These biomarkers were determined in 2007 in sub-
cohort population  among 1,222 women and 758 men participating in the EPIC-Potsdam 
study at the Department of Internal Medicine, University of Tübingen as described elsewhere 
(33). In order to obtain levels for citrate plasma samples comparable to levels obtainable from 
EDTA plasma, all biomarker concentrations were multiplied by 1.16 [women] and by 1.17 
[men] (34). In order be able to include HbA1c, hsCRP and HDL-C in multivariable-adjustment 
models, we measured their concentrations in the remaining cases using the same assays, 
laboratory protocols and in the same laboratory (as described above). We evaluated potential 
differences in the old and new measurements in a subsample of 40 cases and 40 controls with 
repeated measurements. The values were corrected using the mean differences in old and new 
values as correction factors (0.992% for HbA1c, 0.005 mg/L for hsCRP and 2.68 mg/dL for 
HDL-C, respectively). We used the same approach in order to correct omentin values in a 
subset of participants (10 cases and 92 non-cases) which laboratory measurements were 
distorted due to technical reasons in the laboratory. Missing biomarker data for HbA1c (12 
cases, 4.7% of all cases/85 non-cases, 3.7% of all non-cases), HDL-C (10 cases, 4% of all 
cases/1 non-case, 0.04 % of all non-cases) and hsCRP (10 cases, 4% of all cases and 5 non-
cases, 0.21% of all non-cases) were imputed with sex- and disease state specific mean values.  
Statistical analysis 
Differences in cases and non-cases were assessed using Student's paired t test and Wilcoxon's 
signed rank test for continuous variables and by McNemar's test and Bowker's test of 
symmetry for categorical variables. Omentin concentrations were categorized into quartiles 
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based on their distribution in the non-cases in the sub-cohort. Cross-sectional associations 
between plasma concentrations of omentin and selected CRC risk factors were examined 
across omentin quartiles. The associations between concentrations of omentin and metabolic 
biomarkers were evaluated based on age- and sex-adjusted Spearman partial correlation 
coefficients overall and stratified by level of adiposity. Finally, because omentin is implicated 
in both ageing and obesity we visually evaluated the associations of omentin with age and 
obesity parameters using LOESS plots. Hazard ratios as a measure of relative risk (RR) were 
computed using a weighted Cox proportional hazards model, modified for the case-cohort 
design according to the Prentice method (35) . This method was suggested to resemble to the 
highest extent the estimates of the full-cohort estimates. Age was the underlying time variable 
in the counting processes, with entry defined as the participants’ age at the time of 
recruitment/blood collection and exit defined as age at the cancer diagnosis or censoring. We 
computed age-adjusted RRs for each quartile of omentin concentrations compared with the 
lowest quartile. The significance of linear trends across quartiles of omentin concentrations 
was tested by assigning each participant the median omentin value within quartiles as a 
continuous variable. Further, we estimated relative risks associated with increases of log-
transformed omentin concentrations by log 2, which corresponds to a doubling of omentin 
concentrations on the original scale. We evaluated these associations in age- and sex-adjusted 
and multivariable-adjusted models. In the multivariable-adjusted models, in addition to age 
and sex, we used information on a-priori chosen covariates as established risk factors for 
CRC risk including education (in or no training, vocational training, technical school, or 
technical college or university degree), sports activity (0, 0.1–4, or >4 h/week), smoking 
(never, past, or current <20 cigarettes/day or current ≥20 cigarettes/day), alcohol consumption  
(0, 0.1–5, 5.1–10, 10.1–20, 20.1–40, or >40 g/day), fiber intake (g/day), red and processed 
meat intake (g/day), fruit and vegetable intake (g/day), fish intake (g/day), BMI (continuous), 
waist circumference (residually adjusted for BMI). In addition, we also controlled analyses 
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for fasting status (<8 hours, ≥8 hours, unknown). In further analyses, we adjusted the 
associations for metabolic biomarkers previously implicated in higher CRC risk - HbA1c, 
HDL-C and hsCRP (all continuously) - as well as for reported use of anti-diabetic, anti-
hypertensive and anti-inflammatory medication. To test for nonlinearity, we fitted restricted 
cubic splines, at the 5th, 50th, and 95th percentiles of the omentin distribution, to our 
multivariable-adjusted regression model and used the likelihood ratio test to evaluate whether 
a nonlinear term of log-transformed omentin added significant information to the model. We 
estimated the associations according to different strata and tested for effect modification with 
factors that may be relevant for CRC risk (including age, sex, BMI, waist circumference, 
smoking status, alcohol consumption, and according to levels of HbA1c, HDL-C and hsCRP) 
using interaction terms (log-transformed omentin concentrations multiplied by stratum 
variables). To explore whether omentin may add statistically significant information for CRC 
risk assessment beyond established and suspected CRC risk factors (smoking, low physical 
activity, high alcohol consumption, low fibre intake, fruits and vegetables intake, fish intake,  
high BMI, and high waist circumference, HbA1c, HDL-C and hsCRP), we compared the fit of 
the multivariable-adjusted model with a model also including the omentin variable and 
evaluated whether the difference between the two models is statistically significant using a 
likelihood ratio test (LRT) as a standard statistical  procedure for comparing nested models. 
Further, we repeated the main multivariable analyses after excluding cases that occurred 
during the first 3 years of follow-up (n = 59) and participants with omentin concentrations 
below or  above first (≥62ngm/L) and last (<550 ng/mL) decile of omentin distribution (37 
cases/154 non-cases), as well as participants with corrected biomarker measurements (see 
above). Finally, we also evaluated the potential influence of prevalent (n=37) and incident 
(n=4) inflammatory bowel disease (IBD). However, the low number of IBD cases did not 
justify change in the results. All statistical analyses were performed with SAS release 9.1 
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(SAS Institute, Cary, NC). All P values presented are two-tailed; P < 0.05 was considered 
statistically significant.  
Results 
Omentin concentrations were higher among CRC cases compared to the controls (median 
458.6 (IQR, 378.4 - 569.6 ng/mL) in cases versus 395.6 (IQR, 327.7 – 485.5 ng/mL) in 
controls, respectively; Table 1). CRC cases were more likely to be men, to be older and to 
have lower levels of physical activity and fish intake than controls, but higher alcohol 
consumption, BMI and waist circumference, fruit intake and red and processed meat intakes. 
Median concentrations of HbA1c, glucose and hsCRP were higher in CRC cases compared to 
controls whereas HDL-C concentrations were lower (Table 1). Among non-cases, after 
adjustment for sex and fasting status, omentin concentrations were positively associated with 
age, alcohol consumption, systolic blood pressure, and fibre intake (Table 2). In contrast, 
inverse associations were observed for anthropometric indicators and processed meat intake. 
Among the different biomarkers previously implicated in higher CRC risk, higher omentin 
concentrations were positively associated with adiponectin and HDL-C and inversely 
associated with triglycerides in both sexes (Table 3). An inverse association was observed for 
hsCRP; however it was mostly confined to women.  The favorable metabolic profile of 
omentin seemed to be more enhanced in obese individuals compared to non-obese ones 
(Supplementary Table 1).   
In Cox regression analysis, after adjustment for age, sex, smoking, education, alcohol, 
physical activity, fiber, fruits and vegetables, red and processed meat, fish, BMI, and waist 
circumference (residually adjusted for BMI), higher omentin concentrations were associated 
with a higher CRC risk (RR Q4 vs Q1= 2.31, 95% CI: 1.48 – 3.58; Ptrend <0.0001). Based on the 
log-transformed omentin concentrations, an increase by log 2, which corresponds to a 
doubling of omentin concentrations on the original scale, was associated with a significant 
1.98-fold higher risk (95% CI: 1.45-2.73) without apparent differences according to sex 
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(Pinteraction by sex = 0.98). The strength of the association did not essentially change when HbA1c, 
HDL-C and hsCRP were added to the multivariable model individually or in combination 
(Supplementary Figure 2). Further adjustment for antidiabetic, antihypertensive and anti-
inflammatory medication did not substantively change the results (RRQ4 vs Q1 =2.23; 95% CI: 
1.55-3.04; Ptrend = 0.0006). These associations did not deviate from linearity as shown in 
spline regression analysis (Pnon-linearity = 0.20). Thereafter, we tested whether omentin variable 
improves CRC risk assessment beyond established and suspected CRC risk factors by 
comparing multivariable model with a model also including the omentin variable. In this 
analysis addition of omentin statistically significantly improved the multivariable-adjusted 
model beyond established CRC risk factors overall (Figure 1), as well as separately in men 
and women (Supplementary Figure 3A-B). 
Subgroup and sensitivity analyses 
In stratified analysis, no statistically significant interaction was revealed for any of the 
investigated factors with the exception of BMI. Thus, the positive association of omentin with 
CRC risk was retained in participants with a BMI < 30 (Multivariable-adjusted RRcontinuously per 
doubling of omentin concentrations = 2.26; 95% CI: 1.57-3.27; Ptrend <0.0001), whereas among 
participants with BMI ≥ 30 no association was revealed (Multivariable-adjusted RR continuously 
per doubling of omentin concentrations  = 1.07; 95% CI: 0.63-1.83; P interaction by BMI = 0.002; Table 5). In 
further analyses testing linearity assumptions, no statistical deviation from linearity was 
observed [Pnon linearity = 0.43 for participants with BMI<30 (Figure 2-A) and Pnon-linearity = 0.26 
for participants with BMI ≥30 (Figure 2-B)]. Of note, having that no interaction by waist 
circumference and other metabolic factors was observed and the particularly low number of 
cases in subgroup analyses, these stratified results should be interpreted with caution. After 
exclusion of cases that occurred during the first 3 years of study follow-up in the main 
multivariable analysis, the relative risks for omentin concentrations remained unaltered (RR 
continuously per doubling of omentin concentrations = 1.89, 95% CI: 1.25 – 2.97). Exclusion of participants 
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with omentin concentrations below and above first and last decile of omentin distribution, as 
well as participants with corrected biomarker measurements (see above) did not markedly 
change the pattern of the results (data not shown).   
Discusssion 
In this prospective cohort study, higher circulating concentrations of omentin were 
statistically significantly associated with a higher CRC risk, independent of CRC risk factors, 
adiposity and metabolic biomarkers. Furthermore, omentin statistically significantly improved 
risk assessment of CRC beyond established risk factors. The positive association between 
omentin and CRC risk was observed only among participants with BMI less than 30, whereas 
it did not pertain in those individuals whose BMI was equal or above 30. To our knowledge, 
this is the first prospective cohort study on the association between omentin and CRC risk.  
Our overall results for a positive association between omentin and CRC extend those reported 
by a small case-control study which observed higher omentin concentrations in patients with 
colon cancer compared to the healthy controls (18). Similar findings for omentin have also 
been reported with regards to other cancers, such as prostate cancer (36) and mesothelial 
cancer (8). Exact pathophisiological roles of omentin are not well characterized, but 
potentially plausible pathways as explaining mechanisms of our findings for a positive 
association between omentin and CRC risk include (1) acting via inducing chromosomal 
instability; (2) enhancing Akt phosphorylation/activation signaling pathways; and (3) 
reflecting immune response to bacterial pathogen infection, intestinal inflammation and 
inflammatory bowel activity.  
Omentin overexpression has been related to complex translocations indicative of 
chromosomal instability during carcinogenesis (15). Since studies suggest that the majority of 
CRC cases arise through chromosomal instability (37), this pathway could provide a plausible 
link; however the exact initiating mechanisms and relationship with tumor progression are 
still to be elucidated. Novel data has also implicated omentin in the Akt 
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phosphorylation/activation (PI3K) signaling pathways (16,17). PI3K activity is known to be  
associated with the transforming activity of viral oncogenes (38) and to trigger a cascade of 
tumorigenic responses, from cell growth and proliferation to survival and motility (39). In 
addition, a downstream target of Akt  - endothelial nitric oxide synthase (eNOS) - has been 
implicated in tumorigenesis, including colorectal carcinogenesis (40). It can be speculated that 
by promoting activation of the Akt signaling pathway and in turn modulating eNOS, omentin 
may contribute to the pathogenesis of CRC. Omentin may also exert a number of effects 
reflecting cellular immune responses. Thus, omentin is largely expressed in paneth cells, 
goblet cells, endothelial cells, epithelial cells, all of which play a role in immune responses. 
Furthermore, a body of literature has reported omentin to be increased during parasite and 
bacterial infection suggesting its roles in innate immunity and inflammation (19). 
Remarkably, a recent study suggested that omentin selectively binds to pathogenic organisms 
suggesting its functions in microbial surveillance (41). Experimental studies have shown that 
omentin secretion is induced in endothelial cells by IL-6 (42), one of the major inflammatory 
cytokines in response to infection and tissue damage. During infection IL-6 increases omentin 
secretion whereas it decreases expression of anti-inflammatory proteins such as adiponectin, 
thus maintaining energy homeostasis of the host organism. Finally, omentin has also been 
identified as an intestinal lactoferrin receptor able to mediate mucosal immunity functions of 
lactoferrin in the gastrointestinal tract (3). Polymorphisms in the omentin gene have been 
associated with the risk of Crohn’s disease – a form of inflammatory bowel disease (43), 
thereby a change of omentin level may indicate altered immune response to infection, 
facilitating the process of trans-mural inflammation. However, in our data there was no 
indication of inflammatory bowel disease to explain this association.  
Interestingly, the positive association between pre-diagnostic omentin concentrations and 
CRC in our study was confined to non-obese individuals; conversely, a null association was 
revealed in obese participants. Previous studies have shown that omentin concentrations are 
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decreased with obesity and are inversely correlated to insulin resistance (9). Furthermore, 
randomised control trials have shown that weight loss significantly increases plasma omentin 
concentrations (44), whereas hyperinsulinemic induction in healthy individuals reduces them 
(45).  So far there is no evidence on the prospective association between omentin and cancer 
risk in obese individuals.  However, a study conducted in obese women, showed that omentin 
was down-regulated in ovarian cancer patients (45). Collectively, omentin could be down-
regulated by insulin and glucose abundance which may partly explain the lower omentin 
concentrations observed in obese individuals in our study. Future studies are warranted in 
order to confirm these findings and to shed light on potential mechanisms.  
Apart from providing etiological insights, our group is interested in employing novel 
biomarkers for improved disease risk assessment. We therefore tested whether addition of 
omentin variable would add statistically significant predictive value to a model based on 
established lifestyle risk factors for CRC. Our data essentially revealed an ability of omentin 
in improving model discrimination beyond established lifestyle and suspected metabolic CRC 
risk factors. Despite these promising results, further work is needed in order to evaluate the 
predictive value of omentin (i.e. risk reclassification) along with other novel biomarkers in 
improving the risk assessment of CRC. Such work is largely warranted having that the time 
course of cancer initiation and progression from adenoma to cancer provides a window of 
opportunity for prevention. 
Our study benefits from a well-characterized study population embedded into the EPIC-
Potsdam cohort. Data were collected prospectively, thereby eliminating the potential for recall 
bias and reducing the possibility that biomarker levels change as a result of the outcome. 
Furthermore, follow-up proportions exceeded 90%; and all self-reports on incident CRC cases 
were verified through medical records, treating physicians, or death certificates (26). Because 
we used a case-cohort design, our findings are expected to be generalizable to the source 
population without the need to assess biomarker levels in the entire cohort; the external 
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generalizability though may be still limited to populations with similar characteristics. We 
relied on a single baseline blood sample from each participant. Thus, random measurement 
errors may have attenuated the true relation between the biomarkers and the end point. 
However, our preliminary analyses suggested a good reliability of omentin measurements 
over a period of several months (32) arguing against potential influences of within-subject 
variations in biomarker levels over time. Due to the restricted number of cases, in our 
analyses, we did not stratify according to CRC subtypes [colon (proximal/distal) or rectal 
cancer], therefore we are limited in our interpretation of findings to overall CRC. Having that 
previous research has suggested that certain CRC risk factors could be differentially 
associated according to cancer subtype (46), future studies are needed to evaluate CRC 
anatomic site-specific associations. Finally, given the observational nature of our study, our 
results could neither prove nor disprove a causal association between circulating omentin 
concentrations and CRC risk. Replication of findings in other populations is warranted in the 
future research. 
In conclusion, in this prospective cohort study, we provide first lines of evidence for a 
positive association between circulating omentin concentrations and risk of CRC independent 
of established CRC risk factors and a range of metabolic biomarkers. This association was 
largely confined to non-obese individuals, whereas no association was revealed in those 
categorized as obese. Whether up-regulation of immune-related or metabolic pathways may 
underline adiposity specific associations between omentin and CRC risk remains to be 
addressed by future research.  
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Figure legends: 
Figure 1. Predictive ability of pre-diagnostic omentin concentrations beyond established 
lifestyle and metabolic risk factors for colorectal cancer: The EPIC Potsdam Case-Cohort 
Study. The multivariable model  is adjusted for age, sex, smoking status, education, alcohol 
consumption, physical activity, fiber intake, consumption of fruits and vegetables, red and 
processed meat, fish, fasting status, BMI and waist circumference (residually adjusted for 
BMI, HbA1c, HDL-C and hsCRP. P-values for comparison of the fit of the multivariable-
adjusted model with a model also including the omentin variable using a likelihood ratio test 
(LRT) for comparing nested models. 
 
Figure 2: Association of omentin with colorectal cancer in a spline regression model by level 
of adiposity, (Panel A) in participants with BMI <30 and (Panel B) in participants with BMI 
≥30: The EPIC Potsdam Case-Cohort Study.  Restricted cubic splines, at the 5th, 50th, and 
95th percentiles of the omentin distribution were fitted to the multivariable-adjusted 
regression model and likelihood ratio test was used to evaluate whether a nonlinear term of 
log-transformed omentin added significant information to the model. 
 
Abbreviations: EPIC =European Prospective Investigation into Cancer and Nutrition; N = number; BMI = body mass index; SD = standard deviation; HRT = hormonal 
replacement therapy; IQR = interquartile range; hsCRP = high-sensitivity C-reactive protein; HbA1c = glycated hemoglobin; HDL-C = high-density lipoprotein cholesterol. aThe study population in the current analysis is based on participants with available information on circulating omentin concentrations.  
bP-values for the difference between cases and controls were determined by Student’s paired t-test for variables expressed as means and by Mc Nemar’s test and Bowker's test of 
symmetry for variables expressed as percentages. Except for education, vegetable intake and glucose levels, all other difference proved statistically significant (P<0.0001). 
Table 1: Baseline Characteristics of Incident Colorectal Cancer Cases: The EPIC Potsdam Case-Cohort Studya 
Characteristics Cases Subcohortb
N 251 2295 
Socio-demographic factors   
Age, years 56.3 ± 7.3 50.2 ± 9.0 
Female sex, % 40.2 60.4 
Education, %   
 No school degree or primary school 36.3 37.1 
 Technical or professional school 24.3 24.2 
 University degree 39.4 38.7 
Lifestyle factors   
Sports activities, hours/week,  mean  ± SD 0.77 ± 1.76 1.02 ± 1.76 
Smokers,  incl. ex-smokers ≤5 years , % 11.8 7.8 
Baseline alcohol intake, grams/ day,  mean  ± SD 19.1 ± 20.3 14.9 ± 20.9 
BMI, kg/m2, mean (SD) 27.7 ± 4.9 26.1 ± 4.2 
Waist circumference, cm 92.3 ± 13.9 85.9 ± 12.8 
HRT in postmenopausal women, % 10.2 5.9 
Dietary factors    
Fibre intake,  grams/ day,  mean  ± SD 22.4 ± 6.3 22.1 ± 6.8 
Fruits,  grams/ day,  mean  ± SD 146.1±98.4 138.3±93.0 
Vegetables, grams/ day,  mean  ± SD 51.4±34.3 56.8±44.9 
Red meat,  grams/ day,  mean  ± SD 45.1±30.5 43.1±29.4 
Processed meat,  grams/ day,  mean  ± SD 67.7±49.9 61.2±46.5 
Fish,  grams/ day,  mean  ± SD 23.3±20.4 24.4±26.8 
Biomarkers   
Omentin, ng/mL, median (IQR) 459 (378-570) 396 (328-486) 
hsCRP, mg/L,  median (IQR) 1.4 (0.5-2.8) 0.7 (0.2-1.9) 
HbA1c,  [%],  median (IQR) 6.59 (6.39-6.79) 6.42 (6.12-6.74) 
Glucose, mg/dL,  median (IQR) 92.2 (85.2-99.2) 86.8 (80.2-95.1) 
HDL-C, mg/dL,  median (IQR) 44.7 (37.7-51.7) 46.4 (38.9-54.9) 
Table 2. Age- and Sex-adjusted Characteristics, by Quartiles of Omentin within the subcohort (n = 2295): The EPIC Potsdam Case-Cohort Study 
Variables Quartiles of circulating omentin concentrations (median, ng/mL)  Q1 (286.7) Q2 (364.2) Q3 (437.3) Q4 (562.6) P-trend 
Cases/ sub-cohort, N 573 577 573 572  
Demographic and lifestyle factors      
Age, years, mean a 47.5 48.5 51.2 53.4 <0.0001 
Female sex, % b 59 63 60 60 0.98 
University degree, % 43 41 40 40 0.23 
Sports, mean hours per week 0.96 1.00 0.95 1.15 0.07 
Smokers,  incl. ex-smokers ≤5 years, % 17 16 15 11 0.007 
Smokers ≥ 20 cigarettes per day, % 7 7 5 6 0.11 
Alcohol intake, g/day 15.1 16.4 16.5 18.1 0.006 
HRT use, % 16 18 22 23 0.02 
Anthropometric indicators      
BMI, kg/m2,  mean 26.7 26.2 26.3 25.7 0.0002 
Waist circumference, cm,  mean 88.4 87.3 87.3 86.5 0.006 
Hip, cm,  mean 101.6 100.8 100.5 99.6 <0.0001 
Height, cm,  mean 169.4 169.5 168.3 168.3 0.001 
Waist- to- hip ratio,  mean 0.87 0.86 0.86 0.86 0.64 
Waist-to height ratio,  mean 0.52 0.51 0.51 0.51 0.08 
Fat mass, kg,  mean 23.5 22.6 22.1 21.2 <0.0001 
Body fat percent,% 30.5 29.7 29.6 28.7 <0.0001 
Systolic blood pressure, mmHg,  mean 127.8 129.8 131.3 133.3 <0.0001 
Diastolic blood pressure, mmHg,  mean 83.4 84.2 84.9 84.5 0.06 
Dietary factors      
Fibre intake, g /day,  mean 22.2 22.1 22.4 23.0 0.04 
Fruit intake,  g/day,  mean 129.8 130.3 138.0 141.4 0.01 
Vegetable intake,  g/day,  mean 54.6 53.5 55.7 55.7 0.56 
Red meat intake, g/day,  mean 46.2 44.0 46.0 44.9 0.54 
Processed meat intake, g/day,  mean 68.4 62.6 63.3 63.2 0.04 
Fat intake, g/day,  mean 86.4 85.5 85.3 84.2 0.15 
Fish, g/day,  mean 24.3 25.8 24.5 26.2 0.42 
Abbreviations: EPIC =European Prospective Investigation into Cancer and Nutrition; Q = quartile; N = number; BMI = body mass index; g = grams; SD = standard deviation; 
HRT = hormonal replacement therapy. 
aAdjustment only for sex . 
bAdjustment only for age at study recruitment. 
cP for trend from a linear model, calculated using the median omentin concentrations within qaurtiles as a continuous variable, adjusted for age and sex.   
Table 3. Spearman Partial Correlationsa of Omentin with Metabolic Biomarkers within the subcohort overall and by adiposity status (n = 2295): The 
EPIC Potsdam Case-Cohort Study 
Abbreviations: EPIC =European Prospective Investigation into Cancer and Nutrition; CI= confidence interval; hsCRP = high sensitivity C-reactive protein; HbA1c = glycated 
hemoglobin; HDL-C = high-density lipoprotein cholesterol 
aAdjusted for age at study recruitment and sex. 
 
 
 
 
Biomarkers All Men Women R (95% CI) R (95% CI) R (95% CI) 
hsCRP, mg/L -0.10 (-0.14; -0.06) 0.02 (-0.04; 0.09) -0.18 (-0.22; -0.13) 
HbA1c,  [%] -0.00 (-0.04; 0.03) 0.02 (-0.04; 0.08) -0.01 (-0.07; 0.03) 
HDL-C, mg/dL 0.15 (0.11-0.20) 0.13 (0.06; 0.19) 0.17 (0.12; 0.22) 
Triglycerides,  mg/dL -0.10 (-0.14; -0.06) -0.05 (-0.11; 0.02) -0.14 (-0.19;-0.09) 
Adiponectin, mg/dL 0.22 (0.18-0.26) 0.17 (0.10; 0.23) 0.23 (0.20; 0.30) 
Fetuin A, g/L -0.02 (-0.07; 0.01) 0.008 (-0.05; 0.07) 0.05 (-0.10; 0.005) 
Abbreviations: Q =quartile, EPIC =European Prospective Investigation into Cancer and Nutrition; Q = quartile 
aAge- and sex-adjusted models were calculated using Cox proportional-hazard regression modified according to the Prentice method. In the counting processes age was the 
underlying time variable with “entry time” defined as age at baseline and “exit time” as age at cancer event or censoring.   
bThe multivariable model  is adjusted for age, sex, smoking status, education, alcohol consumption, physical activity, fiber intake, consumption of fruits and vegetables, red and 
processed meat, fish, fasting status, BMI and waist circumference (residually adjusted for BMI). 
 
Note: P for interaction by sex = 0.85 
 
Table 4. Relative risks and 95% confidence intervals  of  colorectal cancer across quartiles of  omentin levels:  The EPIC Potsdam Case-Cohort Study 
Model        Quartiles of circulating omentin levels (median, ng/mL) Continuously per doubling of biomarker concentrations P-value Q1 (286.6) Q2 (364.2) Q3 (437.3) Q4 (562.7) P for trend  
All participants 
 
No. of Cases/Controls 34/573 43/577 59/573 115/572    
Age and sex-adjusted RR (95% CI)a 1 [Ref.] 1.10 (0.69-1.78) 1.30 (0.83-2.03) 2.18 (1.43-3.31) <0.0001 1.96 (1.44-2.66) <0.0001 
Multivariable  RR (95% CI)b 1 [Ref.] 1.14 (0.70-1.86) 1.33 (0.85-2.10) 2.31 (1.48-3.58) <0.0001 1.98 (1.45-2.73) <0.0001 
 
Men 
No. of Cases/Controls 22/230 27/208 38/238 63/234    
Age and sex-adjusted RR (95% CI)a 1 [Ref.] 1.03 (0.55-1.91) 1.33 (0.75-2.35) 1.86 (1.09-3.18) 0.005 1.69 (1.13-2.54) 0.01 
Multivariable  RR (95% CI)b 1 [Ref.] 1.00 (0.53-1.88) 1.27 (0.70-2.28) 1.80 (1.01-3.17) 0.01 1.70 (1.10-2.62) 0.02 
 
Women 
No. of Cases/Controls 12/343 16/369 21/335 52/338    
Age and sex-adjusted RR (95% CI)a 1 [Ref.] 1.05 (0.49-2.25) 1.11 (0.53-2.33) 2.49 (1.30-4.82) 0.0005 2.20 (1.39-3.50) 0.0009 
Multivariable  RR (95% CI)b 1 [Ref.] 1.20 (0.53-2.70) 1.27 (0.58-2.75) 3.00 (1.45-6.19) 0.0002 2.36 (1.47-3.77) 0.0004 
Table 5. Multivariable-adjusted RRs (95% CIs) of colorectal cancer  associated with an increase of continuous log-transformed  omentin 
concentrations, in stratified analyses according to CRC risk factors:  The EPIC Potsdam Case-Cohort Study 
Subgroups N cases/ non-cases Continuously per doubling of biomarker concentrationsb 
P-valuec 
Agea    
< 60 years 162/1881 1.97 (1.32-2.93) 0.0009 
≥ 60 years 89/414 2.36 (1.29-4.31) 0.005 
P for interactiond   0.07 
BMI    
< 30  kg/m2 189/1927 2.27 (1.53-3.35) <0.0001 
≥ 30  kg/m2 62/368 1.07 (0.63-1.83) 0.78 
P for interaction   0.005 
Waist circumferencee    
<102 cm in men and <88 cm in women 164/1768 2.25 (1.49-3.39) 0.0001 
≥102 cm in men and ≥88 cm in women 87/527 1.51 (0.86-2.66) 0.14 
P for interactiond   0.55 
Fibre intake    
< 21.5 g/day 114/1164 2.36 (1.47-3.79) 0.002 
≥ 21.5 g/day 137/1131 1.79 (1.09-2.94) 0.02 
P for interactiond   0.53 
Alcohol consumption    
<18.5 mL/day in men and <5 mL/day in women 116/1153 1.87 (1.15-3.06) 0.03 
≥18.5 mL/day in men and ≥5mL/day in women 135/1142 2.12 (1.38-3.26) 0.02 
P for interactiond   0.48 
Smoking status    
Non-smokers 182/1645 2.12 (1.38-3.26) 0.007 
Smokers a 69/650 2.28 (1.17-4.40) 0.01 
P for interactiond   0.53 
HbA1c    
<6.5% 110/1285 2.13 (1.20-3.76) 0.009 
≥6.5% 141/1010 1.79 (1.20-2.67) 0.04 
P for interactiond   0.48 
HDL-C    
<60 mg/dL 231/1939 2.08 (1.47-2.91) <0.0001 
≥60 mg/dL 20/356 0.95 (0.33-2.66) 0.91 
P for interactiond   0.35 
hsCRP  
<3 mg/L 187/1905 1.87 (1.28-1.75) 0.001 
Abbreviations: EPIC =European Prospective Investigation into Cancer and Nutrition; hsCRP = high sensitivity C-reactive protein; HbA1c = glycated hemoglobin; HDL-C = high-
density lipoprotein cholesterol. 
 
aThe stratified variables were excluded from the multivariable adjusted model. 
bModels were calculated using Cox proportional-hazard regression modified according to the Prentice method. In the counting processes age was the underlying time variable 
with “entry time” defined as age at baseline and “exit time” as age at cancer event or censoring.  The multivariable model  is adjusted for age, sex, smoking status, education, 
alcohol consumption, physical activity, fiber intake, consumption of fruits and vegetables, red and processed meat, fish, fasting status, BMI and waist circumference (residually 
adjusted for BMI). 
cP-value for continuous log-transformed omentin concentrations. 
dP-value for statistical interaction on the multiplicative scale between log-transformed omentin concentrations and the stratified variables in a multivariable-adjusted  Cox-
regression analysis. 
eThe cut-off points for stratification according to waiust circumference are based on the National Cholesterol Education Program/Adult Treatment Panel III criteria for defining 
abdominal obesity as a component of the metabolic syndrome definition.  
 
 
≥3 mg/L 64/390 1.86 (0.94-3.67) 0.08 
P for interactiond   0.93 
  
P for difference between models <0.0001 
Figure 1. Predictive ability of  pre-diagnostic omentin concentrations  beyond established lifestyle and metabolic risk factors for colorectal 
cancer: The EPIC Potsdam Case-Cohort Study 
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Figure 2: Association of omentin with colorectal cancer in a spline regression model by level of adiposity, (Panel A) in participants with 
BMI <30 and (Panel B) in participants with BMI ≥30: The EPIC Potsdam Case-Cohort Study  
 
P effect <0.0001 
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